TMEM52B
gene geneOn this page
Also known as FLJ31166
Summary
TMEM52B (transmembrane protein 52B, HGNC:26438) is a protein-coding gene on chromosome 12p13.2, encoding Transmembrane protein 52B (Q4KMG9).
Located in extracellular exosome.
Source: NCBI Gene 120939 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 35 total
- MANE Select transcript:
NM_001384896
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26438 |
| Approved symbol | TMEM52B |
| Name | transmembrane protein 52B |
| Location | 12p13.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ31166 |
| Ensembl gene | ENSG00000165685 |
| Ensembl biotype | protein_coding |
| Entrez | 120939 |
Gene structure
Transcript identifiers
Ensembl transcripts: 13 — 10 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron
ENST00000298530, ENST00000334148, ENST00000381923, ENST00000543484, ENST00000545924, ENST00000546153, ENST00000859442, ENST00000859443, ENST00000859444, ENST00000965685, ENST00000965686, ENST00000965687, ENST00000965688
RefSeq mRNA: 7 — MANE Select: NM_001384896
NM_001079815, NM_001384894, NM_001384895, NM_001384896, NM_001384897, NM_001384898, NM_153022
CCDS: CCDS66314, CCDS8619
Canonical transcript exons
ENST00000543484 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001095454 | 10185330 | 10185368 |
| ENSE00001095458 | 10186420 | 10186589 |
| ENSE00001490295 | 10182550 | 10182593 |
| ENSE00002293090 | 10179032 | 10179628 |
| ENSE00003917506 | 10189896 | 10191804 |
Expression profiles
Bgee: expression breadth ubiquitous, 156 present calls, max score 98.80.
FANTOM5 (CAGE): breadth broad, TPM avg 1.2361 / max 169.4156, expressed in 235 samples.
FANTOM5 promoters (8 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 124142 | 0.3592 | 87 |
| 124137 | 0.3498 | 53 |
| 124141 | 0.1332 | 74 |
| 124135 | 0.1153 | 39 |
| 124139 | 0.1139 | 40 |
| 124134 | 0.0955 | 63 |
| 124136 | 0.0593 | 13 |
| 124138 | 0.0099 | 5 |
Top tissues by expression
243 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| kidney epithelium | UBERON:0004819 | 98.80 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 96.62 | gold quality |
| kidney | UBERON:0002113 | 92.61 | gold quality |
| renal medulla | UBERON:0000362 | 84.58 | gold quality |
| adult organism | UBERON:0007023 | 82.64 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 80.89 | gold quality |
| bone marrow cell | CL:0002092 | 79.88 | gold quality |
| cortex of kidney | UBERON:0001225 | 79.48 | gold quality |
| metanephros cortex | UBERON:0010533 | 78.80 | gold quality |
| metanephros | UBERON:0000081 | 76.87 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 72.97 | gold quality |
| placenta | UBERON:0001987 | 70.19 | gold quality |
| spinal cord | UBERON:0002240 | 70.02 | gold quality |
| bone marrow | UBERON:0002371 | 69.79 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 68.08 | gold quality |
| upper lobe of lung | UBERON:0008948 | 67.55 | gold quality |
| right lung | UBERON:0002167 | 67.28 | gold quality |
| buccal mucosa cell | CL:0002336 | 66.52 | silver quality |
| prefrontal cortex | UBERON:0000451 | 65.85 | gold quality |
| caudate nucleus | UBERON:0001873 | 64.18 | gold quality |
| vermiform appendix | UBERON:0001154 | 63.52 | gold quality |
| putamen | UBERON:0001874 | 63.50 | gold quality |
| amniotic fluid | UBERON:0000173 | 63.12 | gold quality |
| monocyte | CL:0000576 | 62.73 | gold quality |
| leukocyte | CL:0000738 | 61.55 | gold quality |
| lung | UBERON:0002048 | 59.91 | gold quality |
| substantia nigra | UBERON:0002038 | 59.36 | gold quality |
| caecum | UBERON:0001153 | 58.44 | gold quality |
| frontal cortex | UBERON:0001870 | 58.32 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 58.23 | gold quality |
Single-cell (SCXA)
Detected in 5 experiment(s), a significant marker in 5.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-135 | yes | 3749.53 |
| E-CURD-119 | yes | 65.03 |
| E-MTAB-6819 | yes | 48.80 |
| E-HCAD-10 | yes | 27.71 |
| E-ANND-3 | yes | 12.51 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
80 targeting TMEM52B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-4673 | 100.00 | 66.64 | 1490 |
| HSA-MIR-4747-5P | 100.00 | 67.90 | 2681 |
| HSA-MIR-5196-5P | 100.00 | 67.98 | 2761 |
| HSA-MIR-6851-5P | 100.00 | 65.63 | 1294 |
| HSA-MIR-3689D | 100.00 | 66.14 | 1181 |
| HSA-MIR-3064-3P | 100.00 | 70.09 | 1254 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-6759-5P | 99.99 | 66.54 | 785 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-4645-5P | 99.98 | 65.81 | 1284 |
| HSA-MIR-4803 | 99.98 | 71.99 | 3117 |
| HSA-MIR-96-5P | 99.95 | 72.80 | 2140 |
| HSA-MIR-12133 | 99.92 | 71.82 | 2006 |
| HSA-MIR-1271-5P | 99.91 | 71.99 | 1972 |
| HSA-MIR-627-3P | 99.90 | 71.42 | 3316 |
| HSA-MIR-7162-3P | 99.89 | 68.16 | 1682 |
| HSA-MIR-6780A-5P | 99.88 | 66.69 | 2776 |
| HSA-MIR-12119 | 99.87 | 68.35 | 1653 |
| HSA-MIR-182-5P | 99.87 | 74.03 | 2589 |
| HSA-MIR-4307 | 99.82 | 70.45 | 3374 |
| HSA-MIR-1273H-5P | 99.77 | 66.32 | 2471 |
| HSA-MIR-148A-3P | 99.74 | 73.77 | 1700 |
| HSA-MIR-148B-3P | 99.74 | 73.75 | 1700 |
| HSA-MIR-152-3P | 99.74 | 73.75 | 1703 |
| HSA-MIR-4446-5P | 99.72 | 69.19 | 2544 |
| HSA-MIR-30B-3P | 99.70 | 65.76 | 2325 |
| HSA-MIR-3689A-3P | 99.70 | 65.73 | 2306 |
| HSA-MIR-3689B-3P | 99.70 | 65.71 | 2311 |
Literature-anchored findings (GeneRIF, showing 2)
- Study showed that C12orf59 was broadly expressed in normal human tissues with high expression levels in kidney while its expression is beyond detectable in a panel of cancer cell lines. (PMID:26758419)
- TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity. (PMID:33641663)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Tmem52b | ENSMUSG00000030160 |
| rattus_norvegicus | Tmem52b | ENSRNOG00000058653 |
Protein
Protein identifiers
Transmembrane protein 52B — Q4KMG9 (reviewed: Q4KMG9)
All UniProt accessions (2): Q4KMG9, F5H230
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Membrane.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q4KMG9-1 | 1 | yes |
| Q4KMG9-2 | 2 |
RefSeq proteins (7): NP_001073283, NP_001371823, NP_001371824, NP_001371825, NP_001371826, NP_001371827, NP_694567 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR038942 | TMEM52 | Family |
Pfam: PF14979
UniProt features (6 total): signal peptide 1, chain 1, transmembrane region 1, region of interest 1, compositionally biased region 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q4KMG9-F1 | 60.59 | 0.02 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 59 (showing top):
GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, RORA1_01, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP, CHEN_METABOLIC_SYNDROM_NETWORK, STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN, GSE13547_CTRL_VS_ANTI_IGM_STIM_BCELL_2H_DN, PAX3_TARGET_GENES, MIR616_5P, MIR371B_5P, MIR373_5P, MIR96_5P, MIR1827, MIR4446_5P, MIR3124_3P, MIR12119
GO Biological Process (0):
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (2): membrane (GO:0016020), extracellular exosome (GO:0070062)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| binding | 1 |
| cellular anatomical structure | 1 |
| extracellular vesicle | 1 |
Protein interactions and networks
STRING
414 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TMEM52B | AQP6 | Q13520 | 478 |
| TMEM52B | KCNJ1 | P48048 | 470 |
| TMEM52B | PLA2G4E | Q3MJ16 | 469 |
| TMEM52B | SLC12A3 | P55017 | 464 |
| TMEM52B | UMOD | P07911 | 456 |
| TMEM52B | MIOX | Q9UGB7 | 433 |
| TMEM52B | CAPN3 | P20807 | 431 |
| TMEM52B | RPL3L | Q92901 | 402 |
| TMEM52B | TMEM38A | Q9H6F2 | 396 |
| TMEM52B | ANKRD23 | Q86SG2 | 387 |
| TMEM52B | BSND | Q8WZ55 | 378 |
| TMEM52B | TMEM213 | A2RRL7 | 376 |
| TMEM52B | RBP5 | P82980 | 370 |
| TMEM52B | CLEC18B | Q6UXF7 | 370 |
| TMEM52B | MYL11 | Q96A32 | 366 |
IntAct
207 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| GAST | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM86B | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| APOL3 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | TTMP | psi-mi:“MI:0915”(physical association) | 0.560 |
| TUSC5 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | SERP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GPR37L1 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | TMEM54 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | ZDHHC15 | psi-mi:“MI:0915”(physical association) | 0.560 |
| IGFBP5 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | SLC30A8 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM267 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | TMEM60 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | NINJ2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SMIM1 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| VAMP5 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | TMEM128 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | JAGN1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| BET1 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | MS4A13 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TF | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | CSGALNACT2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAL | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| NSG1 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| CNIH1 | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| ITGAM | TMEM52B | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM52B | ORMDL1 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (133): THAP11 (Affinity Capture-MS), NEDD4L (Affinity Capture-MS), NEDD4 (Affinity Capture-MS), RHBDF2 (Affinity Capture-MS), ATP2B4 (Affinity Capture-MS), ANKRD13D (Affinity Capture-MS), FCN1 (Affinity Capture-MS), FLT4 (Affinity Capture-MS), RAB6A (Affinity Capture-MS), ZDHHC9 (Affinity Capture-MS), CORO2A (Affinity Capture-MS), LRBA (Affinity Capture-MS), TAB1 (Affinity Capture-MS), TMEM205 (Affinity Capture-MS), WDR44 (Affinity Capture-MS)
ESM2 similar proteins: A2AR95, A4IHY6, B7ZWI3, D3ZF92, O15165, O43278, O75509, O88204, P98153, P98154, Q0VBF2, Q1L8G6, Q29RU0, Q4KMG9, Q566M8, Q5DTZ6, Q5HZW5, Q5R662, Q5R8E0, Q5RD34, Q5RF74, Q5VUB5, Q61003, Q68FU0, Q6AXS2, Q6NRX0, Q6UWW9, Q6ZPS6, Q6ZUJ8, Q7TQH7, Q86YD5, Q8BGN6, Q8BLD6, Q8BUJ9, Q8R182, Q8TEB7, Q8WUU8, Q91ZV2, Q91ZV3, Q96PD2
Diamond homologs: Q0VBF2, Q4KMG9, Q8NDY8, Q9D702
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
35 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 30 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
646 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 12:10172007:G:C | donor_gain | 1.0000 |
| 12:10189893:CA:C | acceptor_loss | 1.0000 |
| 12:10189894:A:AG | acceptor_gain | 1.0000 |
| 12:10189894:A:AT | acceptor_loss | 1.0000 |
| 12:10189895:G:GA | acceptor_gain | 1.0000 |
| 12:10189895:GC:G | acceptor_gain | 1.0000 |
| 12:10189895:GCT:G | acceptor_gain | 1.0000 |
| 12:10189895:GCTCT:G | acceptor_gain | 1.0000 |
| 12:10170861:C:A | donor_gain | 0.9900 |
| 12:10171996:TAGTA:T | donor_loss | 0.9900 |
| 12:10171998:GTACC:G | donor_loss | 0.9900 |
| 12:10171999:TACC:T | donor_loss | 0.9900 |
| 12:10172000:ACCTT:A | donor_loss | 0.9900 |
| 12:10172026:T:TA | donor_gain | 0.9900 |
| 12:10179123:G:GT | donor_gain | 0.9900 |
| 12:10185328:A:AG | acceptor_gain | 0.9900 |
| 12:10185329:G:GG | acceptor_gain | 0.9900 |
| 12:10186456:T:TA | acceptor_gain | 0.9900 |
| 12:10189892:A:AG | acceptor_gain | 0.9900 |
| 12:10189893:C:G | acceptor_gain | 0.9900 |
| 12:10189895:GCTC:G | acceptor_gain | 0.9900 |
| 12:10179625:CCTGG:C | donor_loss | 0.9800 |
| 12:10179627:TGG:T | donor_loss | 0.9800 |
| 12:10179628:GGTG:G | donor_loss | 0.9800 |
| 12:10179629:GT:G | donor_loss | 0.9800 |
| 12:10179630:TGAGT:T | donor_loss | 0.9800 |
| 12:10179631:GA:G | donor_loss | 0.9800 |
| 12:10185329:GTT:G | acceptor_gain | 0.9800 |
| 12:10186454:T:TA | acceptor_gain | 0.9800 |
| 12:10186484:T:A | acceptor_gain | 0.9800 |
AlphaMissense
558 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 12:10186436:G:C | G52R | 0.950 |
| 12:10186454:T:C | C58R | 0.942 |
| 12:10186437:G:A | G52D | 0.935 |
| 12:10186458:G:A | G59D | 0.913 |
| 12:10185358:T:A | W43R | 0.911 |
| 12:10185358:T:C | W43R | 0.911 |
| 12:10186449:T:G | L56R | 0.904 |
| 12:10186472:T:C | C64R | 0.901 |
| 12:10185367:T:A | W46R | 0.894 |
| 12:10185367:T:C | W46R | 0.894 |
| 12:10186457:G:C | G59R | 0.886 |
| 12:10186449:T:A | L56H | 0.868 |
| 12:10186548:T:A | I89N | 0.865 |
| 12:10186545:T:A | V88D | 0.859 |
| 12:10185348:G:C | W39C | 0.853 |
| 12:10185348:G:T | W39C | 0.853 |
| 12:10185360:G:C | W43C | 0.838 |
| 12:10185360:G:T | W43C | 0.838 |
| 12:10186548:T:G | I89S | 0.827 |
| 12:10186443:T:G | L54R | 0.826 |
| 12:10186446:T:G | L55R | 0.821 |
| 12:10186542:C:T | T87I | 0.797 |
| 12:10186440:C:A | A53E | 0.791 |
| 12:10185365:T:A | I45K | 0.776 |
| 12:10186428:T:A | V49E | 0.770 |
| 12:10186446:T:A | L55H | 0.762 |
| 12:10186452:T:G | L57R | 0.752 |
| 12:10186425:T:G | L48R | 0.743 |
| 12:10186461:T:G | L60R | 0.738 |
| 12:10185361:T:G | Y44D | 0.737 |
dbSNP variants (sampled 300 via entrez): RS1000114217 (12:10171346 G>A), RS1000351781 (12:10180653 A>C), RS1000392931 (12:10168850 A>C), RS1000690907 (12:10180600 A>G), RS1000750203 (12:10185498 T>A), RS1000789153 (12:10168564 G>C), RS1000922865 (12:10186132 G>T), RS1000992075 (12:10192183 A>G,T), RS1001091279 (12:10180178 T>C), RS1001170734 (12:10171934 C>A,T), RS1001320835 (12:10177817 T>A), RS1001383332 (12:10177570 T>C), RS1001427988 (12:10177762 G>C), RS1001433899 (12:10183243 C>A), RS1001531596 (12:10182601 T>C,G)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
17 total (human), top 17 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, increases expression | 3 |
| aristolochic acid I | increases expression | 1 |
| bisphenol A | decreases methylation | 1 |
| perfluorooctanoic acid | decreases expression | 1 |
| nickel sulfate | increases expression | 1 |
| perfluorobutyric acid | decreases expression | 1 |
| dicyclohexyl phthalate | decreases expression | 1 |
| S-(1,2-dichlorovinyl)cysteine | decreases expression | 1 |
| abrine | increases expression | 1 |
| prothioconazole | increases expression | 1 |
| Zoledronic Acid | decreases expression | 1 |
| Benzo(a)pyrene | decreases methylation | 1 |
| Cisplatin | increases expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Valproic Acid | increases expression | 1 |
| Vanadates | decreases expression | 1 |
| Aflatoxin B1 | decreases methylation | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.